Abstract
Objective. The objective of this study was to evaluate the effects of recombinant erythropoietin (EPO) on HIF-1α induced angiogenic pathways in ovarian cancer cells. Methods. Using Western blots and both quantitative and non-quantitative RT-PCR, HIF-1α protein and VEGF transcription levels were assessed. Cell growth was measured using flow cytometry. Results. EPO treatment decreased hypoxia-induced HIF-1α protein levels and VEGF transcription, with no effect on cell growth. Inhibition of HIF-1α signaling by EPO was also observed in MCF-7 breast cancer cells. Conclusion. These novel findings suggest that EPO may exhibit anti-angiogenic properties, thus encouraging further exploration of signaling pathways between EPO and HIF-1α.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
